


CLAIMS

1. A compound of Formula I:



or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium;

or a pharmaceutically acceptable salt of either,

wherein

R^4 is F or CH_3 ,

R^5 is H or C_1 - C_4 alkyl substituted with 0, 1, 2 or 3 F, and


n is 0, 1, 2 or 3.

2. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to claim 1, or a pharmaceutically acceptable salt of either,

wherein


n is 0 or 1.

3. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to claim 1 or claim 2, or a pharmaceutically acceptable salt of either, which is a compound of Formula II:




4. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to claim 3, or a pharmaceutically acceptable salt of either, which is selected from the group consisting of compounds of


Formula IIa, Formula IIb, Formula IIc, Formula IId, Formula IIe and Formula IIf:




Formula IIa;




Formula IIb,




Formula IIc,



Formula IId,




Formula IIe, and



Formula IIlf.


5. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to claim 1 or claim 2, or a

pharmaceutically acceptable salt of either, which is a compound of Formula III:




Formula III.


6. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to claim 5, or a pharmaceutically acceptable salt of either, which is selected from the group consisting of compounds of Formula IIIa, Formula IIIb, Formula IIIc, Formula IIId and Formula IIIe:




Formula IIIa,




Formula IIIb,



Formula IIIc,



Formula IIId, and



Formula IIIe.

7. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to any one of the preceding claims, or a pharmaceutically acceptable salt of either, wherein R^4 is F.

8. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to any one of the preceding claims, or a pharmaceutically acceptable salt of either, wherein R^5 is H.

9. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to claim 1, which is:

(-)-3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 (+)-3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 (-)-3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 (+)-3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 3-[(3,4-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 3-[(2,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 3-[(2,6-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 3-[(2,4-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
 3-[FLUORO(2,4,6-TRIFLUOROPHENYL)METHYL]AZETIDINE,
 3-[FLUORO(2,3,4-TRIFLUOROPHENYL)METHYL]AZETIDINE,
 3-[FLUORO(3,4,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
 3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]-1-METHYL AZETIDINE,
 3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]-1-ETHYL AZETIDINE,
 3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]-1-PROPYL AZETIDINE,
 3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]-1-METHYL AZETIDINE,
 3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]-1-ETHYL AZETIDINE,

3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]-1-PROPYLAZETIDINE,
 3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]-1-METHYLAZETIDINE,
 1-ETHYL-3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
 3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]-1-PROPYLAZETIDINE,
 1-ETHYL-3-[FLUORO(2,3,4-TRIFLUOROPHENYL)METHYL]AZETIDINE,
 3-[FLUORO(2,3,4-TRIFLUOROPHENYL)METHYL]-1-PROPYLAZETIDINE,
 1-ETHYL-3-[FLUORO(3,4,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
 3-[FLUORO(3,4,5-TRIFLUOROPHENYL)METHYL]-1-PROPYLAZETIDINE,
 3-[FLUORO(2,3,5,6-TETRAFLUOROPHENYL)METHYL]AZETIDINE,
 3-[FLUORO(PENTAFLUOROPHENYL)METHYL]AZETIDINE,
 3-[FLUORO(2,3,5,6-TETRAFLUOROPHENYL)METHYL]-1-METHYLAZETIDINE,
 1-ETHYL-3-[FLUORO(2,3,5,6-TETRAFLUOROPHENYL)METHYL]-AZETIDINE, and
 3-[FLUORO(2,3,5,6-TETRAFLUOROPHENYL)METHYL]-1-PROPYLAZETIDINE
 or a pharmaceutically acceptable salt of either.

10. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to claim 1, which is:

(-)-3-[(2,3-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 or a pharmaceutically acceptable salt of either.

11. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to claim 1, which is:

(-)-3-[(3,5-DIFLUOROPHENYL)(FLUORO)METHYL]AZETIDINE,
 or a pharmaceutically acceptable salt of either.

12. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to claim 1, which is:

(-)-3-[FLUORO(2,3,5-TRIFLUOROPHENYL)METHYL]AZETIDINE,
 or a pharmaceutically acceptable salt of either.

13. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to any one of the preceding claims, or a pharmaceutically acceptable salt of either, wherein the compound of Formula I is a

(-)-enantiomer.

14. A compound of Formula I according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to any one of claims 1-14, or a pharmaceutically acceptable salt of either, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.
16. A compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to any one of claims 1-14 or a pharmaceutically acceptable salt of either, for use as a medicament.
17. Use of a compound of Formula I or wherein one or more hydrogen atoms of the compound of Formula I is/are replaced with deuterium according to any one of claims 1-14 for the manufacture of a medicament for the treatment and/or prevention of a disease, disorder and/or condition which is responsive to modulation of monoamines in the cerebral cortex, wherein said disease, disorder and/or condition is selected from the group consisting of dementia, age-related cognitive impairment, cognitive impairment associated with neurodegenerative disorders and/or diseases, autism spectrum disorders, affective disorders, schizophrenia, anxiety disorders, attention deficit hyperactivity disorder (ADHD) and movement disorders.
18. Use according to claim 17, wherein said disease, disorder and/or condition is selected from the group consisting of dementia, age-related cognitive impairment and schizophrenia.